EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease

Olivier Morel, Anh Trung Mai, Liesl Zühlke, Xavier Jouven, Benjamin Marchandot, Gregg Pressman, Ceeya Patton-Bolman, Marco Roffi, Philippe Pibarot

JACC: Asia · 2026-06 · 6 (6) · 839-847

DOI: 10.1016/j.jacasi.2026.03.034 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JACC: Asia, 2026-06. Verfasst von Olivier Morel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hanoi Medical University, Hanoi, Vietnam; Department of Cardiology, University Hospital of Strasbourg, Strasbourg, France; Research Unit UR3074, Tran…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

basic scienceepidemiologyinflammationmitral valverheumatic heart diseaserheumatic heart valve diseasetranslational sciencevalvular heart disease

Autor:innen und Institutionen

  • Hanoi Medical University, Hanoi, Vietnam; Department of Cardiology, University Hospital of Strasbourg, Strasbourg, France; Research Unit UR3074, Translational Cardiovascular Medicine, University of Strasbourg, Strasbour…
  • University of Cape-Town, South Africa, South African Medical Research Council.
  • African Research Network, Dakar, Senegal; Paris Cardiovascular Research Center INSERM U97O, Paris, France.
  • Rwanda Rheumatic Heart Disease Research Network, Kigali, Rwanda; Jefferson Einstein Medical Center, Philadelphia, Pennsylvania, USA; Team Heart, Boston, Massachusetts, USA.
  • Rwanda Rheumatic Heart Disease Research Network, Kigali, Rwanda; Team Heart, Boston, Massachusetts, USA.
  • Division of Cardiology, University Hospitals, Geneva, Switzerland.

Zitieren

APA

Morel, O., Mai, A. T., Zühlke, L., Jouven, X., Marchandot, B., Pressman, G., Patton-Bolman, C., Roffi, M., & Pibarot, P. (2026). SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease. JACC: Asia, 6(6), 839-847. https://doi.org/10.1016/j.jacasi.2026.03.034

Vancouver

Morel O, Mai AT, Zühlke L, Jouven X, Marchandot B, Pressman G, et al. SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease. JACC: Asia. 2026;6(6):839-847. doi:10.1016/j.jacasi.2026.03.034

BibTeX
@article{Morel2026,
  author = {Morel, Olivier and Mai, Anh Trung and Zühlke, Liesl and Jouven, Xavier and Marchandot, Benjamin and Pressman, Gregg and Patton-Bolman, Ceeya and Roffi, Marco and Pibarot, Philippe},
  title = {SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease},
  journal = {JACC: Asia},
  year = {2026},
  volume = {6},
  number = {6},
  pages = {839--847},
  doi = {10.1016/j.jacasi.2026.03.034}
}
Kostenlos starten →